ARK Therapeutics Share Discussion Threads

[filbert3] 29/8/2012 12:42

Turning themselves into another Cobra - probably with the same ultimate result...another example of where they should have just returned remaining funds to shareholders rather rather than trying to keep the gravy train running, even if the passengers have largely changed since the Cerepro (expected) blow up.

[gnnmartin] 29/8/2012 11:01

My holding is hardly worth selling and hardly worth watching so I haven't studied today's accounts, but at first glance they seem dire.
Nigel Martin

[joeblogg2] 29/8/2012 09:31

duncan, u and me both :(( Have sold out at a huge loss now and will wait to see this settle or funding news :((

[duncandisorderly] 29/8/2012 09:30

I always seem to "invest"(laugh)into compannies were the bod seem to get paid handsomely to do a substandard job.They all deserve a p45.

[buywell2] 29/8/2012 09:02

6 August 2012, 6.16am AEST

Animal research provides a flawed model, so why not stop?

Much of the research involving the development of new drugs still uses animals. Apart from moral questions about inflicting pain and death on animals for the purpose of medical research, there are an increasing number of questions about the suitability of using laboratory animals for research into human diseases and drug testing.



There are many examples clearly showing that animal models are not predictive of human health. Recently, a group of scientists wrote an open letter in The Lancet (addressed to the UK prime minister and health secretary) pointing out that more than 90% of new drugs fail in clinical trials.

The authors of the letter say part of the reason for this is the reliance on animal testing to predict drug behaviour in people. They claim that animal tests do this with the same probability as the toss of a coin. And they suggest that animal research be replaced with promising new technologies that increase clinical predictability as well as improving efficiency and cost.

Other researchers have voiced similar concerns. An expert scientific group on phase one (screening for safety) clinical trials in the United Kingdom, for instance, concluded that pre-clinical animal studies may not reproduce the intended pharmacological effect, may give misleading results and, most significantly, may not reflect toxicity in humans.

In the United States, the National Institutes of Health recently suspended all new grants for biomedical and behavioural research on chimpanzees after an expert committee concluded that most such research was unnecessary. And the US National Research Council recommends animal-based tests be replaced as soon as possible with human cell-based assays, in silico (computer) models, and an increased emphasis on epidemiology.

At least one pharmaceutical company has already ceased its animal research program. Denmark-based Novo Nordisk stopped using animals for testing its products in November 2011.

New medicines should be safe and effective, but animal testing is a flawed model. Given that we now have a range of other established and promising methods, we should stop using animals in research and focus on alternatives.

[chrisdgb] 29/8/2012 08:31

6 months of cash only...........very disappointing..

[duncandisorderly] 29/8/2012 08:31

Useless and not surprising

[joeblogg2] 29/8/2012 08:19

Not happy with today's news possibly needing more funding and had hoped for a licence deal by now :(

[joeblogg2] 14/8/2012 08:54

More good news and hope results on the 29th show how under valued this is!!

[filbert3] 25/7/2012 11:48

I didn't know there were any 'leading gene therapy' companies using adenovirus vectors any more! (and it seems even they don't want to have their name directly associated with AKT)

[the_doctor] 27/6/2012 12:11

Yeah - I'm expecting newsflow over the next few weeks to send it back above 3.5p, if not up to the 5p level

[hezza123] 13/6/2012 00:26

Large margin of safety here so nothing to worry about whatsoever. Bought in recently at 2.73p (NCAV is around 3.5p) and will add more if there are any further sharp declines.

[bubbleandleek] 12/6/2012 11:15

very true. still believe in the story, just can't believe the market took such a big position in this and then proceeds to smash them lower than where they bought them. crazy. anyway, i'm buying more for what it's worth.

[joeblogg2] 08/6/2012 13:19

The markets are a mess and that large sale a few weeks back has dented confidence but in time this will come good!!

[blinddarts] 18/5/2012 14:03

As always it's nice to see a director purchase, particularly if it's for their pension. However, I have just been reading up on Peter Keen and boy does it bring it home (again) how some of these guys have created and milked the whole bio start-up business over the past 15-20 years.
The only real winners are the directors, should a product actually work (shock horror) then it's just the icing on the cake for them.

[joeblogg2] 18/5/2012 13:06

This is now well below cash and good value once this overhang clears. Not sure who has got this Lansdown holding as I can't see the MM holding that stock?

[the_doctor] 18/5/2012 12:57

Good call jb2 - I dont see the trades, so always good to have some reports back

[joeblogg2] 18/5/2012 12:07

Got something right for a change, lansdowne sold

[joeblogg2] 17/5/2012 23:51

wow huge trade from the 15th
15-May-1216:36:132.75 20,024,005Sell* 2.802.95550.66k

Hopefully that is the seller cleared out, Lansdowne as they had 20,124,005, we
May get rns in the morning?

[curlly] 17/5/2012 21:29

Whats with the 20000000 trade after close?

[bubbleandleek] 17/5/2012 10:12

pretty benign IMS wouldn't you say? Anyway, these are cheap on a sotp basis. Manufacturing facility not being priced in. sub 3p i'm not sure there's many biotechs around that look cheaper?